Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- CRBU
- Price
- 0.87
- Stock movement up
- +0.01 (1.72%)
- Company name
- Caribou Biosciences Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 79.17M
- Ent value
- 110.33M
- Price/Sales
- 6.90
- Price/Book
- 0.28
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -79.90%
- 3 year return
- -53.53%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
CRBU does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 6.90 |
| Price to Book | 0.28 |
| EV to Sales | 9.61 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 90.55M |
| EPS (TTM) | -1.64 |
| FCF per share (TTM) | -1.45 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 11.47M |
| Gross profit (TTM) | 7.93M |
| Operating income (TTM) | -165.18M |
| Net income (TTM) | -148.12M |
| EPS (TTM) | -1.64 |
| EPS (1y forward) | -2.07 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 69.15% |
| Operating margin (TTM) | -1439.50% |
| Profit margin (TTM) | -1290.81% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 31.97M |
| Net receivables | 1.87M |
| Total current assets | 237.43M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 344.33M |
| Accounts payable | 2.70M |
| Short/Current long term debt | 26.64M |
| Total current liabilities | 32.16M |
| Total liabilities | 63.13M |
| Shareholder's equity | 281.20M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -124.11M |
| Capital expenditures (TTM) | 6.64M |
| Free cash flow (TTM) | -130.75M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -52.67% |
| Return on Assets | -43.02% |
| Return on Invested Capital | -52.45% |
| Cash Return on Invested Capital | -46.30% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.91 |
| Daily high | 0.94 |
| Daily low | 0.81 |
| Daily Volume | 652K |
| All-time high | 30.29 |
| 1y analyst estimate | 12.50 |
| Beta | 2.26 |
| EPS (TTM) | -1.64 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| CRBU | S&P500 | |
| Current price drop from All-time high | -97.11% | -12.89% |
| Highest price drop | -97.50% | -56.47% |
| Date of highest drop | 7 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -74.71% | -11.07% |
| Avg time to new high | 94 days | 12 days |
| Max time to new high | 904 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
79.17M
Marketcap category
Small-cap
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Employees
158
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page